Neodymium-doped Yttrium Aluminum Garnet (Nd:YAG) Laser Treatment for Granular Corneal Dystrophy
Granular Corneal Dystrophy (GCD) is a rare eye disease where deposits form in the cornea, clouding vision. This study tests Neodymium-doped Yttrium Aluminum Garnet (Nd:YAG) laser as a new, less invasive treatment. Unlike surgery, this laser treatment targets and breaks down these deposits with minimal impact. Eligible participants must be over 18, diagnosed with GCD, and able to follow study instructions.
Participants will undergo eye imaging exams and then receive the Nd:YAG laser treatment under local anesthesia. After treatment, antibiotic eye drops may be needed for a week. Follow-up visits will occur one week and three months post-treatment to ensure safety and measure results. The study aims to see if the laser can safely improve vision without causing harm.
- Study involves 2 follow-up visits after treatment.
- Participants should not have active eye inflammation or other specific eye conditions.
- Participants will be carefully monitored, and confidentiality will be maintained.
Study details
NCT06202651
Johns Hopkins University
24 January 2024
Not finding the right Trial?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
FAQs
Learn more about clinical trials
What is a clinical trial?
Why should I take part in a clinical trial?
How long does a clinical trial take place?
Do I get compensated for taking part in clinical trials?
How safe are clinical trials?
Study Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.